Ikena Oncology, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ikena Oncology, Inc. (NASDAQ: IKNA) is a clinical-stage biotechnology company that develops targeted therapies addressing genetic and molecular drivers of cancer, including precision medicines for biomarker-defined patients with unmet needs in oncology. The company offers a pipeline of investigational product candidates such as IK-930, an oral TEAD1-selective small molecule inhibitor of the Hippo signaling pathway; IK-595, a molecular glue designed to trap MEK and RAF proteins for enhanced inhibition of RAS signaling in mutant cancers; and IK-175, an AHR inhibitor evaluated in monotherapy and combination with nivolumab for advanced solid tumors including urothelial carcinomas; alongside earlier-stage assets like IK-364 and PY-265. Ikena operates primarily in the United States, targeting patients with solid tumors and hematologic malignancies across various oncology segments. Founded in 2016 and headquartered in Boston, Massachusetts, the company was originally incorporated as Kyn Therapeutics, Inc., rebranded to Ikena Oncology in 2019 following a strategic shift from immuno-oncology to targeted therapies, and raised $120 million in Series B financing to advance its pipeline. In recent major developments, Ikena discontinued its IK-930 clinical program in May 2024 to prioritize resources on IK-595 and other assets, accompanied by a 53% workforce reduction and exploration of strategic options including potential partnerships, mergers, or asset sales. In December 2024, Ikena entered a definitive merger agreement with Inmagene Biopharmaceuticals, a clinical-stage biotech focused on immunological and inflammatory diseases, which received stockholder approval in July 2025 and closed around July 25, 2025, forming ImageneBio, Inc. (NASDAQ: IMA) with a concurrent $75 million private placement financing from investors including Deep Track Capital, Foresite Capital, RTW Investments, BVF Partners, and OrbiMed, providing approximately $175 million in runway to advance Inmagene's lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody for atopic dermatitis and alopecia areata. The merger included a 1-for-12 reverse stock split effective prior to closing, marking Ikena's transition from oncology to immunology-focused development under new leadership.
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Ikena Oncology Reports Third Quarter 2024 Financial Results
Ikena Oncology Reports Second Quarter 2024 Financial Results
Best Momentum Stocks to Buy for July 12th
New Strong Buy Stocks for July 12th
UPDATE – Ikena Oncology Announces Strategic Update
Ikena Oncology Announces Strategic Update
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround